CPD 2021 | GOCEVENTS

CLICK HERE TO REGISTER NOW!

If you are registered for this meeting, please refer to your emails for the event access. The email subject line you are looking for is " ACCESS GRANTED: GOC’s 20th Continuing Professional Development (CPD)"

Program Objectives

To emphasize the importance of “Wellness” and assess the landscape of “Burnout” in medical personnel and what can be done to identify the problem and help either ourselves or colleagues in need.
To introduce the principle of productivity and how to develop personal strategies to improve productivity wherever applicable in daily life.
To summarize the three “Hot Topic” practice-changing peer-reviewed published articles of 2020.
To discuss the indications for maintenance therapy in ovarian cancer and the possible role of immunotherapy.
To review some rare types of ovarian cancer (mucinous and clear cell) and current treatment philosophies with an emphasis on future clinical research.
To summarize the advances in the adjuvant treatment of endometrial cancer both with respect to radiation and molecular therapy.
To improve the understanding of the problem of lymphedema in the gynecologic oncology population and explore the roles of the supportive care team, physiotherapy, and plastic surgery in the management of the condition.
To understand current projections of global cervical cancer eradication.

Wednesday, April 21st 2021

GOC Social Networking lounge: 5:30pm-6:30pm EST

Welcome and announcements: 6:30pm-6:35pm EST

Dr. Patti Power

Hot Topics of the year

Maintenance Niraparib in first-line ovarian cancer setting: 6:35pm-7:05pm EST

Dr. Anna Tinker

Learning objectives:

Identify the indications for maintenance Niraparib in the first-line setting
Name the benefit of maintenance Niraparib
Anticipate and manage the common side effects of Niraparib

Stretch session: 7:05pm-7:15pm EST

Flex Space

Low Grade Serous Ovarian Cancer- Trials in MEK inhibition: 7:15pm-7:40pm EST

Dr. Taymaa May

Gynecologic Oncologist

Princess Margaret Hospital

Learning objectives:

Review pathogenesis of low grade serous ovarian carcinoma
Discuss current management strategies of women with low grade serous ovarian carcinoma
Review therapeutic options for patients with low grade serous ovarian carcinoma

What is the evidence for HIPEC thus far?: 7:40pm-8:05pm EST

Dr. Joannie Neveu

Gynecologic-Oncologist – Advance Laparoscopy, and Assistant Professor

Bliss Murphy Centre, Memorial University

Learning objectives:

Interpret the data available in regards to oncological outcomes
Explain the perioperative risks and morbidities associated with HIPEC
List the potential challenges in universal adoption of HIPEC

Thursday, April 22nd 2021

GOC Social Networking lounge: 5:30pm-6:30pm EST

Welcome and announcements: 6:30pm-6:35pm EST

Dr. Patti Power

Mucinous Cancers of the Ovary: 6:35pm-7:00pm EST

Dr. Mark Carey

Gynecologic Oncologist

VCH

Learning objectives:

Review the current classifications of mucinous ovarian cancers
Discuss the molecular diversity of mucinous neoplasms
Discuss current treatment options and approaches and their limitations.

Clear Ovarian Carcinoma: New Opportunities for Treatment: 7:00pm-7:25pm EST

Dr. Hal Hirte

Medical Oncologist

Juravinski Cancer Centre

Learning objectives:

Describe the pathophysiology of clear cell ovarian carcinoma
Review the clinical presentation Identify current treatment options
Discuss emerging therapies

Stretch Session: 7:25pm-7:35pm EST

Flex Space

Maintenance Therapy in Front Line Ovarian Cancer: Is it a PARPi for All World?: 7:35pm-8:00pm EST

Dr. Kathleen N. Moore

Stephenson Cancer Center//OUHSC

Learning objectives:

Differentiate the degree of benefit or lack thereof for PARPi, bevacizumab and immunotherapy maintenance in front line ovarian cancer
Interpret the current approved maintenance indications in Canada and how they differ from ROW
Differentiate the molecular profiling used across studies of PARPi efficacy and immunotherapy efficacy and where there are opportunities for improvement
Discuss patient populations where clinical equipoise re maintenance exists and how clinical trials may move us forward.

Strategies and System Change to Mitigate Physician Burnout: 8:00pm-9:00pm EST

Dr. Caroline Gérin-Lajoie

Canadian Medical Association

Learning objectives:

Define and recognize signs and symptoms of burnout in ourselves and others
Identify the potential impact of burnout on individuals and on the health care system
Demonstrate individual and organizational strategies to decrease burnout and increase resilience

Friday, April 23rd 2021

Welcome and announcements: 6:30pm-6:35pm EST

Dr. Patti Power

Hyperfocus: How to Be More Productive in a World of Distraction: 6:35pm-7:30pm EST

Mr. Chris Bailey

Stretch Session: 7:30pm-7:40pm EST

Flex Space

Molecular Classification in Endometrial Cancer: ProMisE for Informed Adjuvant Therapy: 7:40pm-8:05pm EST

Dr. Stephen Welch

Medical Oncologist

London Regional Cancer Program

Learning objectives:

Review data to support prognostic implications of established molecular classifiers in endometrial cancer.
Demonstrate the utility of application of these biomarkers in adjuvant therapy decision-making for resected endometrial cancer, based on data from randomized controlled trials.
Identify the role of molecular classifiers in prospective clinical trials to further improve the outcomes for patients with endometrial cancer.

GOC Social Networking lounge: 8:00pm-8:30pm EST

Saturday, April 24th 2021

GOC Social Networking lounge: 10:00am-10:35am EST

Welcome and announcements: 10:35am-10:40am EST

Dr. Patti Power

Global elimination of cervical cancer - opportunities & challenges: 10:40am-11:05am EST

Dr. Partha Basu, MD, PhD

Deputy Head, Early Detection & Prevention Branch

International Agency for Research on Cancer

World Health Organization

Learning objectives:

Review the strategies for cervical cancer elimination globally
Describe the roadmap to cervical cancer elimination
Assess the opportunities created by the availability of highly effective vaccines and improved screening algorithms
Evaluate the challenges faced by the fragile health systems in the low and middle-income countries to organise the services with quality and equity
Describe how global partnerships can create a 'win win' situation to advance the global elimination of the cancer

Cancer physiatry & considerations in palliative lymphedema: 11:05am-11:30am EST

Dr. George Francis, MD, FRCPC, CSCN(EMG)

Cancer Physiatrist, The University of Calgary

Learning objectives:

Define cancer rehabilitation and name 5 cancer-related impairments that physiatry can address.
Review 3 benefits of manual lymphatic drainage in the palliative cancer patient.
Identify 3 lymphatic devices/garments that can be helpful in the palliative setting.

The Nature of Lymphedema: Management and Prevention: 11:30am-11:55am EST

Ms. Natasha Grant

Physiotherapist, Jewish General Hospital

Learning objectives:

Comprehend the role of physiotherapy in detecting and treating lymphedema.
Identify three interventions physiotherapists use to treat lymphedema.
Describe two indications for referral to a lymphedema specialist.

Stretch Session: 11:55am-12:05pm EST

Flex Space

Novel surgical treatments for secondary lymphoedema: 12:05pm-12:30pm EST

Dr. Marie-Pascale Tremblay-Champagne

Plastic surgeon, University of Montreal

Learning objectives:

Summarize the 2 most common microsurgical procedures for lymphedema: vascularized lymph node transfers and lymphatic ovenous anastomoses
Identify patients who may be candidates for these surgical procedures
Predict realistic benefits from these surgical procedures, in order to better counsel patients

Closing remarks: 12:30pm EST

Dr. Patti Power

Taymaa May

Dr. Taymaa May is a gynecologic oncologist at Princess Margaret Cancer Center and an associate professor at the University of Toronto. Her research focuses on surgical innovation and translational research in the field of ovarian cancer. Dr. May is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. Dr. May is the surgical oncology lead for Toronto central south, Cancer Care Ontario, Ontario Health and a member of the Gynecologic Oncology Group of Ontario executive. Dr. May is the current chair of the GOC's Annual General Meeting and is a member of GOC’s board of directors.

Mark Carey

Dr. Carey completed his medical degree and Obstetrics & Gynecology residency at the University of Western Ontario, a fellowship in Gynecologic Oncology at the University of Toronto and McMaster University, and a research fellowship in the Department of Systems Biology at the University of Texas, MD Anderson Cancer Centre.

Joannie Neveu

Dr. Joannie Neveu graduated medical school at the University of Sherbrook and pursued her
OBGYN residency at Memorial University. She then went to the University of Calgary and
completed her fellowship in Minimally Invasive Surgery- Advance Laparoscopy before joining the
team at Université de Montréal for a 2 year fellowship in Gynecologic Oncology. Dr. Neveu’s
special interests include: Advancement in surgical approach; Robotic surgery, and
Multi-Disciplinary Oncology Projects.

George Francis

Cancer Physiatrist at The University of Calgary

Marie-Pascale Tremblay-Champagne

Dr. Tremblay-Champagne completed her medical studies at McGill University’s Faculty of Medicine in 2009. Her training in plastic surgery was completed at the University of Montreal in 2014. She then embarked on a fellowship year in Seattle with Dr Peter Neligan, to subspecialize in breast reconstruction, oncologic microsurgical reconstruction and lymphedema microsurgery. Since 2015, Dr. Tremblay Champagne has started her practice in Montreal. She is part of the University of Montreal’s Plastic Surgery Division and residency training program, where a large part of her practice is dedicated to oncologic microsurgical reconstruction and lymphedema surgery.

Hal Hirte

Dr. Hirte is a staff physician in the Department of Medical Oncology at the Juravinski Cancer Centre in Hamilton Ontario. He is an associate professor in the Department of Oncology at McMaster University, and has a cross appointment in the Department of Obstetrics and Gynecology. He obtained his undergraduate medical degree from the University of Toronto, Faculty of Medicine in 1980, and completed his internal medicine training at the University of Toronto. He subsequently entered the Princess Margaret Hospital/University of Toronto Medical Oncology Programme and received his subspecialty certification in 1985. He went on to do a two year research fellowship in the development of therapeutic immunoconjugates at the Biologic Response Modifiers Program at the National Cancer Institute of the US in Frederick, Maryland, followed by additional two year post-doctoral fellowship in tumour immunology in the Host Resistance Programme at McMaster University in Hamilton. Dr. Hirte’s clinical practice has focused and Gynecologic and CNS malignancies and early phase clinical trials. He has been active as an investigator in phase I studies of targeted agents, and in phase II and III trials for CNS and gynecological malignancies. His research interests are focussed on the assessment of novel molecular targeted therapies, including signalling inhibitors, anti angiogenic and immune therapies, and the determination of relevant clinical and molecular endpoints in studies using such agents. He is the co chair of the Canadian Cancer Clinical Trials Group (CCTG) Gynecologic Oncology Disease Site Committee and is a member of the Canadian CCTG CNS Disease Site Committee. In addition, he sits on grants review panels for the Canadian Cancer Society Research Institute, the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. He is a member of the executive of the Society of Gynecologic Oncologists of Cancer in the role of
secretary treasurer.

Caroline Gérin-Lajoie

Dr. Caroline Gérin-Lajoie is a bilingual psychiatrist and assistant professor at the University of Ottawa, Faculty of Medicine. She is also cross-appointed to the Palliative Care Division of the Department of Medicine. She has worked at The Ottawa Hospital (TOH) since 2000 and at the Cancer Centre since 2007, in leadership, teaching and clinical roles. She completed a five-year term as director of the Faculty Wellness Program, Faculty of Medicine, in December 2018 and has worked as the TOH Medical Director of Physician Health and Wellness from 2014 to 2020. This role also included physician engagement from December 2016 to 2018. She joined the Canadian Medical Association in January 2019 as it’s first Vice-President of Physician Health and Wellness. In 2020, her title and the scope of the team was expanded to Physician Wellness and Medical Culture. Dr. Gérin-Lajoie graduated from the OMA-CMA Master’s Certificate Physician Leadership Course in June 2014. She has presented provincially, nationally and internationally on topics related to psychosocial oncology, physician health and disruptive behaviour. In collaboration with her colleagues at TOH, she has been working on implementing resiliency initiatives for physicians, trainees and staff. This work has resulted in a two-year grant from the Mach Gaensslen Foundation to evaluate a resiliency pilot that could ultimately lead to the development of a corporate health plan at TOH. She has also contributed or collaborated on research projects in the area of physician wellness. In her personal life, Dr. Gérin-Lajoie enjoys spending time at the family cottage with her husband, three children and two stepchildren.

Stephen Welch

Dr. Stephen Welch joined the Department of Oncology and the Division of Medical Oncology in London, Ontario in September 2007. His clinical duties involve treatment of patients with gynecologic and gastrointestinal cancer. Dr. Welch is the Division Chair of Medical Oncology and Medical Director of the Baines Cancer Clinical Research unit in London. He currently serves as co-chair of the Endometrial Cancer Working Group of the Canadian Clinical Trials Group and is a member of the National Cancer Institute Uterine Task Force.

Kathleen Moore

Dr. Moore is currently a Professor in the Division of Gynecologic Oncology at the University of Oklahoma. She is the Associate Director
or Clinical Research and the Director of the Phase I Drug Development Unit at the Stephenson Cancer Center at the University of Oklahoma. She received her MD from the University of Washington School of Medicine in 2000. She completed her residency in Obstetrics and Gynecology at Magee Womens Hospital, Pittsburgh, PA in 2004 and went on to complete her fellowship in Gynecologic Oncology at the University of Oklahoma in 2007. She has been on faculty at the University of Oklahoma since 2007. Nationally she serves as the NRG Chair for Ovarian Cancer, Associate Director for GOG Partners and has participated in many NCI sponsored clinical trial initiatives. She has authored over 200 manuscripts and has lead phase I through III trials including those with registration intent.

Chris Bailey

Mr. Chris Bailey provides audiences with practical and tactical advice for becoming more productive. Called “the most productive man you’d ever hope to meet” by TED Talks, a “productivity mastermind” by Fast Company, “a quirky and energetic guide through the productivity thicket” by the Harvard Business Review, and an “all-around productivity guru” by Wired Magazine, Bailey will transform how you and your audience think about productivity in the workplace and beyond.

Bailey is the international bestselling author of Hyperfocus and The Productivity Project—which have been published in 20 languages and sold hundreds of thousands of copies around the world. He is also the author of the Audible Original, How to Train Your Mind, and is writing a third book for Penguin Books, on how calm improves our productivity. On top of the books, Bailey writes a weekly column at ALifeofProductivity.com, which is read by tens of thousands of people every week. His latest TED Talk, “How to Get Your Brain to Focus”, has been viewed over 7 million times.

Bailey’s approach is unique: he believes there is no one-size-fits-all solution to becoming more productive. Instead, he has spent the last decade experimenting with every productivity tactic under the sun, separating what works from what doesn't. That experimentation has run the gambit from curious to ridiculous and saw him meditating for 35 hours in a week, using his smartphone for only an hour a day, working 90-hour weeks, and much more. Combining lessons from his books, the latest research, and what he found during these productivity experiments, Bailey offers useful tidbits on how we can apply this advice to our daily lives in order to accomplish more.

To date, Bailey has written hundreds of articles on productivity, and has garnered coverage in media as diverse as The New York Times, The Wall Street Journal, New York magazine, The Huffington Post, Harvard Business Review, Lifehacker, GQ, TED, Wired Magazine, BBC, Fortune, and Fast Company.

Anna Tinker

Dr. Anna Tinker is a Medical Oncologist at the British Columbia Cancer, Vancouver Centre and a Clinical Associate Professor in the Department of Medicine at the University of British Columbia. Her clinical expertise is in the treatment of women with gynecologic cancers. Her research interests are in the area of clinical trial development, immunotherapy, and translational research. She is presently the Chair of the Provincial Gyne Oncology Tumour Group, and is also the Director of OvCaRe’s Ovarian Cancer Outcomes Unit. She is an active member of the Canadian Cancer Trials Group, participating as study chair, a member of the Ovarian Cancer Working Group Committee and on the Investigational New Drug Committee and she serves on the Gynecologic Cancers Steering Committee – Ovarian Task Force for the National Cancer Institute (US).

Partha Basu

Dr. Partha Basu is the Deputy Head, Early Detection, Prevention & Infection Branch of International Agency for Research on Cancer (IARC). He was Head of Gynecological Oncology at Chittaranjan National Cancer Institute, India before joining IARC in 2015. Dr. Basu leads a wide range of collaborative research projects, which includes the following: • Evaluation of new technologies to improve breast cancer early diagnosis in India • Evaluation of status and performance of cancer Screening in five continents (CanScreen5) • Randomized controlled trial to compare thermal ablation, cryotherapy and LLETZ for cervical precancer management in Zambia • Evaluation of a single dose of HPV vaccine • Assessing the population level impact of HPV vaccination on prevention of cervical HPV infection • Improving cervical cancer screening in vulnerable women in Europe • Evaluation of artificial intelligence based device in detection of cervical neoplasias • WHO Knowledge Academy - developing comprehensive learning programme on cervicalcancer screening • Evaluation of colorectal cancer screening demonstration project in LMICs Dr. Basu’s projects are funded by National Institute of Health (NIH, USA), Bill & Melinda Gates Foundation, European Commission, American Cancer Society, Medical Research Council (UK), Norwegian Research Council, Swiss Cancer Research, Lalla SalmaFoundation (Morocco) etc. Dr. Basu’s publications may be accessed at https://scholar.google.com/citations?hl=en&view_op=list_works&gmla=AJsN-F4ZD6-

Natasha Grant

Natasha Grant is the clinical coordinator and clinician for the Jewish General Hospital Lymphedema Clinic at the Segal Cancer Centre in Montreal, Quebec. In May 2007, she spearheaded the clinic as the first hospital based service in Montreal that evaluates and treats patients for lymphedema secondary to cancer-related treatments. Ms. Grant was previously an integral part of the McGill Cancer Nutrition Rehabilitation (CNR)program both at the Montreal General and the Jewish General hospitals, respectively.